Author: Odeh, Fadwa; Nsairat, Hamdi; Alshaer, Walhan; Ismail, Mohammad A.; Esawi, Ezaldeen; Qaqish, Baraa; Bawab, Abeer Al; Ismail, Said I.
Title: Aptamers Chemistry: Chemical Modifications and Conjugation Strategies Cord-id: d93i22pi Document date: 2019_12_18
ID: d93i22pi
Snippet: Soon after they were first described in 1990, aptamers were largely recognized as a new class of biological ligands that can rival antibodies in various analytical, diagnostic, and therapeutic applications. Aptamers are short single-stranded RNA or DNA oligonucleotides capable of folding into complex 3D structures, enabling them to bind to a large variety of targets ranging from small ions to an entire organism. Their high binding specificity and affinity make them comparable to antibodies, but
Document: Soon after they were first described in 1990, aptamers were largely recognized as a new class of biological ligands that can rival antibodies in various analytical, diagnostic, and therapeutic applications. Aptamers are short single-stranded RNA or DNA oligonucleotides capable of folding into complex 3D structures, enabling them to bind to a large variety of targets ranging from small ions to an entire organism. Their high binding specificity and affinity make them comparable to antibodies, but they are superior regarding a longer shelf life, simple production and chemical modification, in addition to low toxicity and immunogenicity. In the past three decades, aptamers have been used in a plethora of therapeutics and drug delivery systems that involve innovative delivery mechanisms and carrying various types of drug cargos. However, the successful translation of aptamer research from bench to bedside has been challenged by several limitations that slow down the realization of promising aptamer applications as therapeutics at the clinical level. The main limitations include the susceptibility to degradation by nucleases, fast renal clearance, low thermal stability, and the limited functional group diversity. The solution to overcome such limitations lies in the chemistry of aptamers. The current review will focus on the recent arts of aptamer chemistry that have been evolved to refine the pharmacological properties of aptamers. Moreover, this review will analyze the advantages and disadvantages of such chemical modifications and how they impact the pharmacological properties of aptamers. Finally, this review will summarize the conjugation strategies of aptamers to nanocarriers for developing targeted drug delivery systems.
Search related documents:
Co phrase search for related documents- absence presence and acid inducible gene: 1
- absence presence and acute lymphoblastic leukemia: 1
- absence presence and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- absence presence and live cell imaging: 1, 2
- absence presence and local concentration: 1
- absence presence and long plasma: 1
- absence presence and loop region: 1, 2
- absence presence and low affinity: 1, 2
- absence presence and low density: 1, 2, 3
- absence presence and low density lipoprotein: 1
- absence presence and low toxicity: 1, 2
- absence presence and luciferase gene: 1, 2, 3, 4
- absence presence and lung cancer: 1, 2, 3, 4
- absence presence and lung cancer cell: 1
- absence presence and lymphoblastic leukemia: 1, 2
- absence presence and lymphoma cell: 1, 2
- absence presence and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
Co phrase search for related documents, hyperlinks ordered by date